AI-generated analysis. Always verify with the original filing.
Alto Neuroscience entered a Securities Purchase Agreement on March 16, 2026, for a private placement of 2,900,000 shares of common stock at $20.00 per share and pre-funded warrants to purchase 3,100,000 shares, expecting gross proceeds of approximately $120 million before expenses. Proceeds will fund ALTO-207 development through Phase 3 and potential NDA in treatment resistant depression.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry Into A Material Definitive Agreement. Private Placement of Common Stock and Warrants On March 16, 2026, Alto Neuroscience, Inc. (the “ Company ”) entered
. The securities described above under Item 1.01 have not been registered under the Securities Act of 1933, as amended (the “ Securities Act ”). Based in part u
Other Events. On March 16, 2026, the Company issued a press release entitled “Alto Neuroscience Announces $120 Million Private Placement Financing.” The full te
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Form of Pre-Funded Warrant. 10.1 Form of Securities Purchase Agreement, dated March
Material Agreement